Option Care Health reached a new 12-month peak following Morgan Stanley’s decision to raise its price target from 35.00 to 38.00 and maintain an overweight rating. Trading volume surged to over 2.5 million shares, reflecting heightened investor interest. Deutsche Bank also increased its objective to 36.00 with a buy recommendation, while Wall Street Zen upgraded to buy. Of the 14 analysts covering the company, 11 currently rate it as a buy or stronger, contributing to a consensus Moderate Buy rating and an average target of 37.17.

Management reported preliminary fourth-quarter net sales in a range of 1.46–1.47 billion, up from 1.35 billion a year earlier, and non-GAAP net income of 73.8–79.0 million, versus 75.5 million last year. Full-year EPS guidance was raised to 1.72–1.76, above the consensus of 1.64, while revenue guidance for FY2026 was set at 5.8–6.0 billion, slightly below consensus of 6.1 billion. Investors responded positively to the revenue beat and the raised EPS outlook, viewing it as validation of the company’s profitability trajectory.

Director Harry M. Jansen Kraemer, Jr. acquired 38,000 shares at an average cost of 25.98, boosting his stake by 10.1% to 413,390 shares, now valued at approximately 10.7 million. Insider ownership stands at 0.64%, while institutional investors hold 98.05% of the float. Recent filings show modest new stakes by boutique funds, including positions valued between 26,000 and 38,000, signaling ongoing confidence among sophisticated buyers.

With a market capitalization of 5.64 billion, a price-to-earnings ratio of 28.18 and a PEG ratio of 2.17, Option Care Health trades at a premium relative to peers. The company’s beta of 0.80 indicates lower volatility, and its debt-to-equity ratio of 0.85 reflects moderate leverage. Liquidity ratios are healthy, with a current ratio of 1.56 and a quick ratio of 1.05, underscoring solid short-term financial flexibility as management pursues growth in home infusion services.